Tirzepatide lowers risk for cardiovascular events in real-world setting

Tirzepatide reduced risk for major adverse cardiovascular events among adults with type 2 diabetes and established atherosclerotic cardiovascular disease, according to real-world data published in The BMJ. As Healio previously reported, the SURPASS-CVOT trial found tirzepatide (Mounjaro, Eli Lilly) conferred a similar reduction in risk for CV events as dulaglutide (Trulicity, Eli Lilly) among